Shares of Cellebrite DI Ltd. (NASDAQ: CLBT) plummeted 31% on Thursday after the digital forensics software maker reported quarterly recurring revenue that missed its own guidance and slashed its full-year growth outlook. The abrupt leadership transition announced the same day further rattled investors, raising fresh questions about the company's execution capabilities.
The stock fell to an intraday low of $9.58, breaching its previous 52-week trough of $11.02. With roughly 249 million shares outstanding, the selloff erased nearly $1.2 billion in market capitalization. At 1:02 p.m. EDT, shares traded at $10.475, down $4.775 from Wednesday's close of $15.25, on volume of 23.5 million shares.
Cellebrite's annual recurring revenue (ARR) for the second quarter came in at $507.8 million, up 21% year-over-year but $2.2 million below the lower end of the company's prior guidance range of $510 million to $513 million. Revenue of $131.1 million landed within the $130 million to $133 million forecast, while adjusted EBITDA of $31.8 million exceeded the top of the $29 million to $31 million projection. Net revenue retention stood at 117%, two percentage points higher than in the first quarter.
Despite the modest dollar shortfall, the market reaction was severe, reflecting a broader credibility reset. Management trimmed the midpoint of its 2026 ARR guidance by 2.6% to $555 million and lowered the revenue midpoint by 1.8% to $558 million, while simultaneously raising the adjusted EBITDA midpoint by 2.6% to $156 million. The revised outlook implies ARR growth of 14% to 16%, down from the previous 18% to 19% range.
Newly appointed CEO Shiven Ramji attributed the underperformance to extended sales cycles and slower-than-expected expansion from the Inseyets platform transition. “We are taking action to improve execution going forward,” he said in the company's SEC filing. Ramji, who joined as president of products and technology in May, took over immediately from Thomas Hogan in what the company described as a planned leadership change.
The product roadmap remains uneven. Genesis posted its first revenue during the quarter, and Guardian secured a significant FedRAMP contract, but management adopted a cautious tone regarding near-term contributions from new offerings.
Analyst targets, all set before Thursday's plunge, now appear optimistic. DA Davidson maintains a Buy with a $20 target, Needham has a $15 target, and JPMorgan's Overweight rating carries a $24 target. Even the lowest target, Needham's $15, implies 43% upside from the current intraday price, but investors are advised to wait for updated commentary before viewing that gap as a buying opportunity.
Looking ahead, Cellebrite guided third-quarter revenue between $145 million and $148 million and ARR in the range of $524 million to $528 million. Achieving these targets would indicate whether delayed deals shifted into the period or were lost entirely.
Key risks include prolonged government sales cycles, sluggish Inseyets conversions, new CEO execution, budget constraints, export regulations, and geopolitical exposure tied to Israel. However, robust free cash flow—$144.2 million over the trailing twelve months, a 28% margin—and accelerating Genesis adoption could provide some support.
The market's 31% drop signals that improved profitability alone cannot offset the erosion of confidence in Cellebrite's growth trajectory. The company must now prove it can convert its strong retention rate into faster net-new ARR expansion.